Business
Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, CA / ACCESSWIRE / September 5, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, CA / ACCESSWIRE / September 5, 2023 / Ensysce Biosciences, Inc. (\"Ensysce\" or the \"Company\") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that its management has been invited to present at the H.C. Wainwright 25th Annual Global Investment Conference (the \"conference\") taking place in New York, NY on September 11-13, 2023.The Company's Chief Executive Officer, Dr. Lynn Kirkpatrick, and Chief Financial Officer, Dave Humphrey, will be available for one-on-one meetings during the conference. Interested parties can register for and view the webcast of the presentation as they discuss their ‘Next Generation' of analgesics for severe pain and their Phase 3 development plans here. For more information about the event or to schedule a one-on-one meeting with Ensysce's management, please contact Ensysce's Investor Relations at [email protected] management is scheduled to present as follows:H.C. Wainwright 25th Annual Global Investment ConferenceDate: Monday, September 11, 2023 - Wednesday, September 13, 2023Presentation Time: September 11, 2023, at 12:00 p.m. Eastern TimeWebcast: Please click hereLocation: Lotte New York Palace Hotel, New York, NYFor more information on the conference, visit https://hcwevents.com/annualconference/.To access the latest investor presentation please click here.About Ensysce BiosciencesEnsysce Biosciences is a clinical-stage company applying transformative chemistry to improve prescription drug safety. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing ‘Next Generation' analgesics for severe pain. Ensysce's products are anticipated to provide safer options for patients and assist in preventing medication overdose. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.Forward-Looking StatementsStatements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of ...